@WorldHealthNews | Newsroom

The Content Was Refreshed: 19 Jan 2019 | 03:02:22

WorldHealthNews Live

Joseph Daskalakis’ son was born New Year’s Eve, a little over a week into the current government shutdown, and about 10 weeks before he was expected.
Posted: January 19, 2019, 1:08 am
The drug was previously designated a "breakthrough therapy."
Posted: January 19, 2019, 1:08 am
A long-term care facility where an Arizona woman in a vegetative state was raped and gave birth last month is looking into another abuse allegation
Posted: January 19, 2019, 1:08 am
No one has been convicted of a felony in the Flint water investigation, three years after the start of a state criminal probe
Posted: January 19, 2019, 1:08 am
Lawsuits are seeking to hold the drug industry accountable for the opioid crisis in the US, but one prominent family is getting a lot of the scrutiny
Posted: January 19, 2019, 1:08 am
The World Health Organization says it is seeing increasing reports of misconduct reported by staffers within the U.N. health agency, describing the trend as "a positive thing."
Posted: January 19, 2019, 1:08 am
Kevin Curry shares recipes for men and women in his new book.
Posted: January 19, 2019, 1:08 am
"GMA Day" producer Dani Kipp tried out The DB Method for 30 days.
Posted: January 19, 2019, 1:08 am
Betty Bienias said she was shocked to find out she was expecting triplets - two of which had been conceived naturally.
Posted: January 18, 2019, 3:34 pm
Patients in England are struggling to get hold of drugs such as painkillers and anti-depressants.
Posted: January 18, 2019, 3:34 pm
Doctors say Carter Cookson, who is on life support, needs an organ transplant as soon as possible.
Posted: January 18, 2019, 3:34 pm
Every three seconds in the UK, someone has an asthma attack which could be life-threatening, a charity says.
Posted: January 18, 2019, 3:34 pm
Easy ways you can take care of your digestive system as it recovers from the festive excesses
Posted: January 18, 2019, 2:22 pm
Research from Exeter University details that haemochromatosis could affect up to 20 times more people than earlier figures suggested - here's what to look out for
Posted: January 18, 2019, 2:22 pm
PMID:  J Microsc Ultrastruct. 2018 Oct-Dec;6(4):171-176. PMID: 30464888Abstract Title:  Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle.Abstract:  Cannabinoids have been increasingly gaining attention for their therapeutic potential in treating various cardiovascular disorders. These disorders include myocardial infarction, hypertension, atherosclerosis, arrhythmias, and metabolic disorders. The aim of this review is to cover the main actions of cannabinoids on the cardiovascular system by examining the most recent advances in this field and major literature reviews. It is well recognized that the actions of cannabinoids are mediated by either cannabinoid 1 or cannabinoid 2 receptors (CBRs). Endocannabinoids produce a triphasic response on blood pressure, while synthetic cannabinoids show a tissue-specific and species-specific response. Blocking cannabinoid 1 receptors have been shown to be effective against cardiometabolic disorders, although this should be done peripherally. Blocking CBRs may be a useful way to treat atherosclerosis by affecting immune cells. The activation of CBRs was reported to be useful in animal studies of myocardial infarction and cardiac arrhythmia. Although cannabinoids show promising effects in animal models, this does not always translate into human studies, and therefore, extensive clinical studies are needed to truly establish their utility in treating cardiovascular disease.

read more

Posted: January 18, 2019, 2:07 pm
PMID:  J Neurochem. 2018 Dec 6. Epub 2018 Dec 6. PMID: 30520038Abstract Title:  Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: A systematic review and meta-analysis.Abstract:  Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder that results from motor neuron damage. Cannabinoids have been proposed as treatments for ALS due to their anti-excitotoxicity, anti-oxidant, and anti-inflammatory effects. Pre-clinical studies in mice models of ALS have been published using a range of cannabinoid formulations and doses. To date, there has been no rigorous evaluation of these trials to assess a potential cannabinoid treatment effect. This review and meta-analysis was undertaken to provide evidence for or against a treatment effect of cannabinoids in murine ALS models. Evidence of a treatment effect in mice may provide motivation for trials in human ALS. We identified a total of 10 studies; 9 studies using cannabinoid treatment in transgenic SOD1-G93A ALS-model mice and 1 study in TDP-43 transgenic mice. 8 of the 9 studies that used SOD1-G93A mice expressed similarly high copy numbers of the transgene whilst one study used a low-copy number line. Outcomes evaluated were survival time and disease progression. The latter was measured by motor function and bodyweight decline. Meta-analysis of the mean difference in survival time across the 7 studies showed an increase in survival of 3.84 days (95% CI 0.35 to 7.32 days; P =0.031) for cannabinoid treated compared to control SOD1-G93A mice. It was not possible to conduct meta-analyses for motor function decline or weight loss. However, 8 of 9 studies reported significant improvements in measures of motor function decline and 1 reported non-significant improvements. Weight loss was significantly attenuated in 4 of 5 studies reporting this measure whilst the other study reported a non-significant attenuation. This review provides some evidence for the efficacy of cannabinoids in prolonging survival time in an ALS mouse model. A delay in disease progression is also suggested following cannabinoid treatment though it was not possible to consolidate the results from reviewed studies. However, studies have moderate to high risk of bias and are highly heterogeneous. Although this review provides some evidence to support the conduct of a cannabinoid trial in human ALS, more standardized studies on specific cannabinoids are necessary before supporting therapeutic potential of cannabinoids in treating patients with ALS. This article is protected by copyright. All rights reserved.

read more

Posted: January 18, 2019, 2:07 pm
PMID:  Am J Clin Dermatol. 2018 Dec 12. Epub 2018 Dec 12. PMID: 30542832Abstract Title:  Cannabinoids: Potential Role in Inflammatory and Neoplastic Skin Diseases.Abstract:  The endocannabinoid system is a complex and nearly ubiquitous network of endogenous ligands, enzymes, and receptors that can also be stimulated by exogenous compounds such as those derived from the marijuana plant, Cannabis sativa. Recent data have shown that the endocannabinoid system is fully functional in the skin and is responsible for maintaining many aspects of skin homeostasis, such as proliferation, differentiation, and release of inflammatory mediators. Because of its role in regulating these key processes, the endocannabinoid system has been studied for its modulating effects on both inflammatory disorders of the skin and skin cancer. Although legal restrictions on marijuana as a Schedule I drug in the USA have made studying cannabinoid compounds unfavorable, an increasing number of studies and clinical trials have focused on the therapeutic uses of cannabinoids. This review seeks to summarize the current, and rapidly expanding field of research on the broad potential uses of cannabinoids in inflammatory and neoplastic diseases of the skin.

read more

Posted: January 18, 2019, 2:07 pm
PMID:  Inflammopharmacology. 2019 Jan 4. Epub 2019 Jan 4. PMID: 30610735Abstract Title:  Anti-inflammatory mechanisms of cannabinoids: an immunometabolic perspective.Abstract:  A number of studies have implicated cannabinoids as potent anti-inflammatory mediators. However, the exact mechanism by which cannabinoids exert these effects remains to be fully explained. The recent resurgence in interest regarding the metabolic adaptations undergone by activated immune cells has highlighted the intricate connection between metabolism and an inflammatory phenotype. In this regard, evidence suggests that cannabinoids may alter cell metabolism by increasing AMPK activity. In turn, emerging evidence suggests that the activation of AMPK by cannabinoids may mediate an anti-inflammatory effect through a range of processes. First, AMPK may promote oxidative metabolism, which have been shown to play a central role in immune cell polarisation towards a tolerogenic phenotype. AMPK activation may also attenuate anabolic processes which in turn may antagonise immune cell function. Furthermore, AMPK activity promotes the induction of autophagy, which in turn may promote anti-inflammatory effects through various well-described processes. Taken together, these observations implicate cannabinoids to mediate part of their anti-inflammatory effects through alterations in immune cell metabolism and the induction of autophagy.

read more

Posted: January 18, 2019, 2:07 pm
PMID:  Pharmacol Res. 2019 Jan 4. Epub 2019 Jan 4. PMID: 30616019Abstract Title:  Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids.Abstract:  Type-2 diabetes (T2D) increases the risk of dementia by˜5-fold, however the mechanisms by which T2D increases dementia risk remain unclear. Evidence suggests that the heightened inflammation and oxidative stress in T2D may lead to disruption of the blood-brain barrier (BBB), which precedes premature cognitive decline. Studies show that vascular-targeted anti-inflammatory treatments protect the BBB by attenuating neuroinflammation, and in some studies attenuate cognitive decline. Yet, this potential pathway is understudied in T2D-associated cognitive impairment. In recent years, therapeutic potential of cannabinoids has gained much interest. The two major cannabinoids, cannabidiol and tetrahydrocannabinol, exert anti-inflammatory and vascular protective effects, however few studies report their potential for reversing BBB dysfunction, particularly in T2D. Therefore, in this review, we summarize the current findings on the role of BBB dysfunction in T2D-associated dementia and consider the potential therapeutic use of cannabinoids as a protectant of cerebrovascular BBB protection.

read more

Posted: January 18, 2019, 2:07 pm
PMID:  Front Pharmacol. 2018 ;9:994. Epub 2018 Aug 31. PMID: 30233372Abstract Title:  LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice.Abstract:  There is a substantive clinical literature on classical hallucinogens, most commonly lysergic acid diethylamide (LSD) for the treatment of alcohol use disorder. However, there has been no published research on the effect of LSD on alcohol consumption in animals. This study evaluated the effect of LSD in mice using a two-bottle choice alcohol drinking paradigm. Adult male C57BL/6J mice were exposed to ethanol to develop preference and divided into three groups of equal ethanol consumption, and then treated with single intraperitoneal injection of saline or 25 or 50μg/kg LSD and offered water and 20% ethanol. The respective LSD-treated groups were compared to the control group utilizing a multilevel model for repeated measures. In mice treated with 50 μg/kg LSD ethanol consumption was reduced relative to controls (= 0.0035), as was ethanol preference (= 0.0024), with a group mean reduction of ethanol consumption of 17.9% sustained over an interval of 46 days following LSD administration. No significant effects on ethanol consumption or preference were observed in mice treated with 25μg/kg LSD. Neither total fluid intake nor locomotor activity in the LSD-treated groups differed significantly from controls. These results suggest that classical hallucinogens in the animal model merit further study as a potential approach to the identification of targets for drug discovery and investigation of the neurobiology of addiction.

read more

Posted: January 18, 2019, 2:07 pm
PMID:  Prog Brain Res. 2018 ;242:69-96. Epub 2018 Aug 31. PMID: 30471683Abstract Title:  d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.Abstract:  Depression and anxiety are psychiatric diagnoses commonly associated with low quality of life and low percentage of responsiveness by patients treated with currently available drugs. Thus, research into alternative compounds to treat these disorders is essential to guarantee a patient's remission. The last decade has witnessed a revamped interest for the application of psychedelic medicine for the treatment of mental disorders due to anecdotal reports and clinical studies which show that low doses of d-lysergic acid diethylamide (LSD) and psilocybin may have antidepressant effects. LSD and psilocybin have demonstrated mood-modulating properties likely due to their capacity to modulate serotonergic (5-HT), dopaminergic (DA) and glutamatergic systems. LSD, belonging to the category of"classic halluginogens,"interacts with the 5-HT system through 5HT, and 5HTreceptors, with the DA system through Dreceptors, and indirectly also the glutamatergic neurotransmission thought the recruitment of N-methyl-d-aspartate (NMDA) receptors. Randomized clinical studies have confirmed its antidepressant and anxiolytic effects in humans. Thus, in this chapter, we will review the pharmacology of psychedelic drugs, report the most striking clinical evidence which substantiate the therapeutic potentials of these fascinating compounds in mood disorders, and look into the horizon of where psychedelic medicine is heading.

read more

Posted: January 18, 2019, 2:07 pm
PMID:  Inflammopharmacology. 2019 Jan 1. Epub 2019 Jan 1. PMID: 30600471Abstract Title:  Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-κB signaling pathway.Abstract:  BACKGROUND: Carfilzomib (CFZ), a proteasome inhibitor approved by the FDA to treat multiple myeloma, may cause nephrotoxicity.HYPOTHESIS: Rutin is a bioflavonoid with antioxidant properties. We aimed to examine whether rutin protects the kidney from CFZ-induced nephrotoxicity.STUDY DESIGN: This study aimed to demonstrate the effect of rutin on CFZ-induced renal injury via the inhibition of oxidative stress and inflammation.METHODS: Wistar albino rats were divided into six groups (n = 6): Group 1 (normal control; NC) was administered normal saline for 3 weeks; Group 2 (CFZ/toxic group) received CFZ [4 mg/kg, intraperitoneal (i.p.) injection] twice weekly for 3 weeks; Group 3 (standard treatment group) was administered CFZ (4 mg/kg, i.p.) and olmesartan (2 mg/kg, p.o.)for 3 weeks; Group 4 was administered CFZ (4 mg/kg, i.p.) and rutin (10 mg/kg, p.o.) for 3 weeks; Group 5 was administered CFZ (4 mg/kg, i.p.) and rutin (20 mg/kg, p.o.) for 3 weeks; and Group 6 was administered CFZ (4 mg/kg, i.p.) and rutin (40 mg/kg, p.o.) for 3 weeks. We carried out haematological and biochemical analyses, determined oxidative stress, caspase-3 activity, and protein levels, and performed a histopathological evaluation to confirm CFZ-induced nephrotoxicity and its prevention by rutin administration.RESULTS: Exposure to only CFZ significantly (p 

read more

Posted: January 18, 2019, 2:07 pm
PMID:  Int Rev Psychiatry. 2018 Aug 13:1-14. Epub 2018 Aug 13. PMID: 30102082Abstract Title:  Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.Abstract:  Cancer is highly prevalent and one of the leading causes of global morbidity and mortality. Psychological and existential suffering is common in cancer patients, associated with poor psychiatric and medical outcomes. Promising early-phase clinical research (1960s to early 1970s) suggested a therapeutic signal for serotoninergic psychedelics (e.g. psilocybin, LSD) in treating cancer-related psychiatric distress. After several decades of quiescence, research on psychedelic-assisted therapy to treat psychiatric disorders in cancer patients has resumed within the last 2 decades in the US and Europe. This review article is based on a systematic search of clinical trials from 1960-2018 researching the therapeutic use of psychedelic treatment in patients with serious or terminal illnesses and related psychiatric illness. The search found 10 eligible clinical trials, with a total of 445 participants, with the vast majority of the patients having advanced or terminal cancer diagnoses. Six open label trials, published between 1964 and 1980 (n = 341), suggested that psychedelic therapy (mostly with LSD) may improve cancer-related depression, anxiety, and fear of death. Four RCTs trials were published between 2011 and 2016 (n = 104), mostly with psilocybin treatment (n = 92), and demonstrated that psychedelic-assisted treatment can produce rapid, robust, and sustained improvements in cancer-related psychological and existential distress.

read more

Posted: January 18, 2019, 2:07 pm
PMID:  Front Psychol. 2018 ;9:1424. Epub 2018 Aug 15. PMID: 30174629Abstract Title:  DMT Models the Near-Death Experience.Abstract:  Near-death experiences (NDEs) are complex subjective experiences, which have been previously associated with the psychedelic experience and more specifically with the experience induced by the potent serotonergic,,-Dimethyltryptamine (DMT). Potential similarities between both subjective states have been noted previously, including the subjective feeling of transcending one's body and entering an alternative realm, perceiving and communicating with sentient 'entities' and themes related to death and dying. In this within-subjects placebo-controled study we aimed to test the similarities between the DMT state and NDEs, by administering DMT and placebo to 13 healthy participants, who then completed a validated and widely used measure of NDEs. Results revealed significant increases in phenomenological features associated with the NDE, following DMT administration compared to placebo. Also, we found significant relationships between the NDE scores and DMT-induced ego-dissolution and mystical-type experiences, as well as a significant association between NDE scores and baseline trait 'absorption' and delusional ideation measured at baseline. Furthermore, we found a significant overlap in nearly all of the NDE phenomenological features when comparing DMT-induced NDEs with a matched group of 'actual' NDE experiencers. These results reveal a striking similarity between these states that warrants further investigation.

read more

Posted: January 18, 2019, 2:07 pm
An air traffic controller is just one employee locked into the terms of a health plan because of the ongoing federal shutdown. It's meant his child's hospital bills are "out-of-network."
Posted: January 18, 2019, 1:31 pm
The Content Was Refreshed: 19 Jan 2019 | 03:02:22